52 Biomarker Discovery & Development CROs

What is biomarker discovery and development, and when do you need it?

A biomarker is anything you can measure that tells you something true about a drug or a disease: whether the compound reached its target, whether the pathway moved, whether a patient is likely to respond, or whether an organ is taking damage. Biomarker discovery is the hunt for those signals. Biomarker development is the unglamorous work that follows: turning a promising signal into an assay that is reproducible, quantitative, and defensible. The discovery half tends to be exploratory and broad (omics screens, untargeted profiling). The development half is narrow and rigorous, and it is where most programs underinvest.

You need this work earlier than most teams plan for it. Pharmacodynamic and target-engagement biomarkers belong in preclinical pharmacology, because a clean readout that your drug actually engaged the target in vivo is what lets you set a dose and defend a mechanism. Predictive and patient-selection biomarkers, the ones that decide who goes into a trial, have to be discovered preclinically and qualified before first-in-human, or you end up enrolling a population the drug was never going to help. Safety biomarkers (the classic kidney and liver injury panels, plus emerging tissue-specific markers) ride alongside toxicology. If you wait until the clinic to think about biomarkers, you are usually retrofitting, and retrofitting is slow and expensive.

Concretely, the bench work spans a lot of platforms: RNA-seq and single-cell sequencing, mass spectrometry and targeted proteomics, multiplex immunoassays (MSD, Luminex), flow and mass cytometry, ELISA and Simoa for low-abundance analytes, ddPCR and qPCR for circulating nucleic acids, IHC and digital pathology, and the bioinformatics layer that turns any of it into a usable signature. A program rarely needs all of these. The decision a buyer is actually making is which one or two readouts will move a go/no-go gate, and which CRO runs that specific platform well.

What does a biomarker discovery and development CRO actually do?

The work splits roughly into discovery, assay development, and assay validation, and a buyer is usually shopping for a specific slice rather than the whole arc. On the discovery side, a CRO will run omics and profiling experiments on your samples (tumor, blood, tissue, preclinical models), then apply statistics and machine learning to surface candidate markers that separate responders from non-responders or treated from control. The deliverable is a shortlist of candidates with evidence behind them, not a finished test.

Assay development takes a candidate and builds a measurement around it: selecting the platform, optimizing antibodies or primers, setting the dynamic range, and proving the readout is specific and reproducible across operators and days. Validation then puts that assay through a defined protocol covering accuracy, precision, sensitivity, specificity, parallelism, and stability, with the rigor scaled to how the data will be used. A fit-for-purpose exploratory biomarker needs less than one that will support a regulatory claim or a companion diagnostic. The strongest CROs are explicit about which tier they are building to, and they will tell you when you are paying for more validation than the decision requires (or dangerously less).

How do you choose a biomarker discovery and development CRO?

Platform fit and assay rigor matter more here than raw size, because a biomarker is only as good as the assay underneath it. The questions below separate a partner who hands you a defensible, transferable assay from one who hands you a number you cannot trust or reproduce.

• Quality and GxP status: confirm whether the work is exploratory (fit-for-purpose) or needs GLP for safety biomarkers, or GCLP for clinical-sample analysis. Companion-diagnostic intent eventually pulls in CLIA and IVD design controls, so flag that early.
• Platform and modality fit: match the CRO to your actual readout (proteomics, NGS, flow cytometry, IHC and digital pathology, ddPCR, Simoa). Strength in one platform does not imply strength in another. Ask for method validation reports in your assay class.
• Capacity and lead time: assay development plus validation commonly runs several months before a single study sample is read. Confirm scientist availability, sample throughput, and whether method development and sample analysis can run on the timeline your program gate needs.
• Indication and biology fit: relevant disease-area experience (your tumor type, your tissue, your model) shortens development and avoids artifacts. Ask for case studies in the same biology, not just the same instrument.
• Data quality and bioinformatics: you want documented acceptance criteria, audit-ready raw data, honest reporting of failed markers, and a bioinformatics team that explains its statistics rather than handing over a black-box signature.
• Region and regulatory track record: if the data supports an IND, a label claim, or a CDx, ask how often their methods have held up in FDA or EMA review, and whether they can support a biomarker qualification or CDx pathway.
• Sample logistics and stability: cold-chain handling, biobanking, chain-of-custody, and validated stability windows. Mishandled samples quietly invalidate otherwise good assays.
• IP and confidentiality: confirm you own the assay, the candidate markers, and any signature derived from your samples, and check how platform-background IP and data-sharing are handled before you send material.